Diseases

Unlocking the full value of life-course immunization: A key to sustainable healthcare

An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.

Increasing community testing to clear the NHS backlog

Doris-Ann Williams MBE, CEO, BIVDA, calls for increased community testing as a way to clear the NHS backlog and deal with the increasing number of people who are living with undiagnosed diseases in the UK.

How to naturally lower your cholesterol levels

Dr Deborah Lee, Dr Fox Online Pharmacy, shares her tips on how to naturally lower your cholesterol levels without using medication.

Managing heart failure in 2021 and beyond

Professor Carlos Aguiar, Chair of the European Society of Cardiology (ESC) Communication Committee and spokesperson for Heart Failure, outlines the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.

Factory farming, zoonotic disease and the risk of pandemics

Compassion in World Farming Research Manager dissects some of the dangers of the factory farming industry, discussing the spread of zoonotic diseases.

What are zoonotic diseases?

Captain Casey Barton Behravesh of the U.S. Public Health Service, and Director of the CDC One Health Office highlights the CDC’s efforts to nationally and internationally prevent zoonotic diseases.

Changing the treatment paradigm in Inflammatory Bowel Diseases

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.

Public health response to dementia

Chris Lynch, Deputy CEO at Alzheimer’s Disease International, sheds light on the WHO Global action plan on the public health response to dementia 2017-2025.

What is Osteogenesis Imperfecta (OI)?

Patricia Osborne, Chief Executive of the Brittle Bone Society, tells us what we need to know about Osteogenesis Imperfecta.

Patient and Public Involvement at the heart of brain research

Professor Mogens Hørder, PPI expert, JPND’s management board member and representative of member state Denmark, discusses how Patient and Public Involvement (PPI) is at the heart of neurodegenerative disease research.

Organ transplants fell by a third during first wave of COVID-19

Organ transplants performed during the first wave of COVID-19 fell by a third compared to 2019, according to a new study.

Supporting families living with Huntington’s Disease

Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.

Clinical trial to test third COVID-19 vaccine for people with weakened immune systems

A new clinical trial will investigate whether a third COVID-19 vaccine dose gives a stronger immune response for people with weakened immune systems.

The future of regenerative cell therapeutics

Tobias Deuse, Cardiac Surgeon and Scientist at University of California San Francisco, reveals to us the future of regenerative cell therapeutics.

A changing landscape for type 1 diabetes

Dr Faye Riley, Senior Research Communications Officer at Diabetes UK, charts a changing landscape for type 1 diabetes.

NHS GP says long COVID patients “shouldn’t suffer in silence”

NHS GP and lead GP at Numan, Dr Luke Pratsides tells us everything he knows about the symptoms of long COVID and what’s being done to tackle this novel disease.

New mosquito control tools are critical

Leo Braack, Malaria Consortium’s Senior Vector Control Specialist, recounts the ongoing battle against vector-borne diseases and shares why the need for new mosquito control tools has become critical.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders